SCHEMBL480707

SCHEMBL480707

COc1ccc(Cl)c(CC(=O)c2ccc(=O)n(C)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
BRD4 O60885 1/20 0.41
CTSD P07339 1/20 0.40
KMT2A Q03164 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 2/20 0.40
AKR1C3 P42330 2/20 0.39
AKR1C4 P17516 1/20 0.39
PTGS1 P23219 1/20 0.39
AKR1C2 P52895 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.38
MAOA P21397 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MAOB P27338 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20440100 0.78 NPC1 (0.53) KDM4ECTSDKMT2ANPC1RAB9A
SCHEMBL480465 0.76 KDM4E (0.45) KDM4EBRD4KMT2ANPC1RAB9A
SCHEMBL474042 0.75 CDYL2 (0.49) KMT2ANPC1RAB9A
SCHEMBL480934 0.75 EPHX2 (0.38) KDM4EBRD4SMN1; SMN2HTT
SCHEMBL474378 0.73 CBX7 (0.46) KMT2AMEN1SMN1; SMN2HSD17B10MAPT
SCHEMBL4970738 0.73 RAB9A (0.50) KMT2ANPC1RAB9AMEN1SMN1; SMN2
SCHEMBL16836022 0.72 HSD17B10 (0.50) KDM4ECTSDAKR1C3PTGS1AKR1C2
SCHEMBL473974 0.72 HSD17B10 (0.68) KDM4ECTSDKMT2AMEN1AKR1C3
SCHEMBL29458589 0.72 HSD17B10 (0.68) KDM4ECTSDKMT2AMEN1AKR1C3
SCHEMBL2316645 0.72 HSD17B10 (0.50) KDM4ECTSDNPC1RAB9AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 KDM4E 1499/4885BRD4 3300/4885CTSD 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.